价格

BAXALTA US INC

6415 S Florida Ave, Lakeland, Florida, 美国

概览

试验阶段分布

阶段

试验数

占比

4 期

100.0%

试验状态分布

进行中（未招募）

66.7%

尚未招募

33.3%

药物批准

按机构分类的批准

NPRA

National Pharmaceutical Regulatory Agency

药物批准

近期批准

ADYNOVATE 1000IU Powder and Solvent for Solution for Injection

NPRA

2025-11-28

ADYNOVATE 1500IU Powder and Solvent for Solution for Injection

NPRA

2025-11-28

ADYNOVATE 750IU Powder and Solvent for Solution for Injection

NPRA

2025-11-28

ADYNOVATE 3000IU Powder and Solvent for Solution for Injection

NPRA

2025-11-28

ADYNOVATE 2000IU Powder and Solvent for Solution for Injection

NPRA

2025-11-28

ADYNOVATE 250IU Powder and Solvent for Solution for Injection

NPRA

2025-11-28

ADYNOVATE 500IU Powder and Solvent for Solution for Injection

NPRA

2025-11-28

FLEXBUMIN 20%, ALBUMIN (HUMAN), USP,20% SOLUTION

NPRA

2025-11-28

FLEXBUMIN 25%, ALBUMIN (HUMAN), USP, 25% SOLUTION

NPRA

2025-11-28

资讯

暂无资讯文章

返回机构列表

BAXALTA US INC

概览

试验阶段分布

试验状态分布

相关临床试验

该机构主办的试验（3）

Phase IV study of Brentuximab Vedotin in Hodgkin Lymphoma

Safety of ADVATE in previously treated Indian patients for treatment of mild , moderate and severe bleeding episodes in Haemophilia A

Safety of ADVATE in previously treated Indian patients for treatment of mild , moderate and severe bleeding episodes in Haemophilia A

药物批准

按机构分类的批准

近期批准

资讯